{
  "source": "PA-Med-Nec-Palforzia.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 2182-8\nProgram Prior Authorization – Medical Necessity\nMedication Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp]\nP&T Approval Date 1/2020, 3/2020, 3/2021, 3/2022, 3/2023, 3/2024, 3/2025, 4/2025\nEffective Date 7/1/2025\n1. Background:\nPalforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp]is an oral immunotherapy indicated\nfor the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental\nexposure to peanuts. Palforzia is approved for use in patients with a confirmed diagnosis of\npeanut allergy. Initial dose escalation may be administered to patients aged 1 through 17 years.\nUp-dosing and maintenance may be continued in patients1 year of age and older. Palforzia is to\nbe used in conjunction with a peanut-avoidant diet.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Palforzia will be approved based on the following criteria:\na. Diagnosis and clinical history of peanut allergy as documented by both of the following:\n(1) A serum peanut-specific IgE level of greater than or equal to 0.35 kUA/L\n(2) A mean wheal diameter that is at least 3mm larger than the negative control on skin-\nprick testing for peanut\n- AND -\nb. One of the following\n(1) Both of the following\n(a) Patient is 1 to 17 years of age\n(b) Patient is in the initial dose escalation phase therapy\n-OR-\n(2) Both of the following:\n(a) Patient is 1year of age and older\n(b) Patient is in the up-dosing or maintenance phase of therapy\n-AND-\n© 2025 UnitedHealthcare Services, Inc.\n1\nc. Used in conjunction with a peanut-avoidant diet\n-AND-\nd. Patient does not have any of the following\n(1) History of eosinophilic esophagitis (EoE) or eosinophilic gastrointestinal disease\n(2) History of severe or life-threatening episode(s) of anaphylaxis or anaphylactic shock\nwithin the past 2 months\n(3) Severe or poorly controlled asthma\n-AND-\ne. Prescribed by or in consultation with an allergist/immunologist\n-AND-\nf.",
    "tening episode(s) of anaphylaxis or anaphylactic shock\nwithin the past 2 months\n(3) Severe or poorly controlled asthma\n-AND-\ne. Prescribed by or in consultation with an allergist/immunologist\n-AND-\nf. Prescriber is certified/enrolled in the Palforzia REMS Program\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Palforzia will be approved based on the following criteria:\na. Documentation of positive clinical response to Palforzia therapy\n-AND-\nb. Used in conjunction with a peanut-avoidant diet\n-AND-\nc. Prescribed by or in consultation with an allergist/immunologist\n-AND-\nd. Prescriber is certified/enrolled in the Palforzia REMS Program\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n© 2025 UnitedHealthcare Services, Inc.\n2\n3. Additional Clinical Programs:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may apply\n4. References:\n1. The PALISADE Group of Clinical Investigators. AR101 Oral Immunotherapy for Peanut Allergy.\nN Engl J Med. 379(21):1991-2001.\n2. Palforzia [prescribing information]. Bridgewater, NJ: Aimmune Therapeutics, Inc.; July 2024.\nProgram Prior Authorization – Medical Necessity – Palforzia\nChange Control\n1/2020 New program.\n3/2020 Updated background section. Added age requirements for initial phase\nand up-dosing/maintenance phase. Added that it is being used along with\na peanut-avoidant diet. Added the prescriber is certified/enrolled in the\nPalforzia REMS Program. Updated references.\n3/2021 Annual review. Updated references.\n3/2022 Annual review. No changes.\n3/2023 Annual review. No ch",
    "t. Added the prescriber is certified/enrolled in the\nPalforzia REMS Program. Updated references.\n3/2021 Annual review. Updated references.\n3/2022 Annual review. No changes.\n3/2023 Annual review. No changes.\n3/2024 Annual review. Updated references.\n3/2025 Annual review. No changes.\n4/2025 Updated age range based on update to prescribing information.\n© 2025 UnitedHealthcare Services, Inc.\n3"
  ]
}